New York, United States—Aug 4, 2022—BOC Sciences released a complete set of ADC drug development services for CD19, CD22, EGFR, and other tumor targets, dedicated to helping pharmaceutical partners drive forward the development of innovative cancer treatments.

In addition to classical targets such as HER2, newly discovered targets like folate receptor, tissue factor, LIV-1, and CEACAM have also made significant progress. Meanwhile, drugs targeting these new targets are currently under close investigation in various clinical phases. Since BOC Sciences has been engaged in preclinical ADC drug development for years, its experts have built a full list of ADC-targeting cancer surface antigens to help pharmaceutical clients in novel ADC drug development.

To bring more ADC breakthroughs to the market, BOC Sciences released its comprehensive set of ADC development services for diverse targets. Its scientists can utilize advanced antigen screening techniques and related antibody modification processes to advance antigens and antibodies' binding affinity and specificity. These high-quality custom ADCs are suitable for tasks such as proof-of-concept, target validation, and acting as a control to provide efficacy comparison for new ADC development and projects.

BOC Sciences also have a complete ADC analytical development toolbox that can be leveraged to select the most suitable analytical strategies for specific bioconjugate characterization as well as to establish lot release and stability assay panels. In addition, the extensive payload and linker libraries, as well as all sorts of mAb library generation and screening platforms, are also available at BOC Sciences for the development of candidate matrix preparation and evaluation.

Its cGMP grade laboratory facilities and systems for ADCs/bioconjugates are designed to meet the ISO and GMP requirements. Based on the robust ADC platform, its experts have implemented a wide range of ADC design and construction services for cancer therapy, including breast cancer, gastric cancer, ovarian cancer, lung cancer, etc.

"Our targeted development technology also covers analytical services for total antibody, conjugated antibody, unloaded antibody and free/dissociated drug. Our expertise and services can assist customers in candidate selection and optimization in different phases of ADC drug development. We hope to accelerate ADC drug discovery with our joint endeavor through optimizing our ADC platform and producing more efficient and low-cost ADC products," the marketing manager at BOC Sciences said.

About BOC Sciences
BOC Sciences' mission is to profoundly speed up drug research and development by delivering a new class of ADC therapeutics. Partnering with companies and academic groups all over the world, including most of the top biopharmaceutical companies, BOC Sciences helps researchers deliver ADC drugs to the market by providing all preclinical activities and one-stop ADC solutions targeted to different receptors. BOC Sciences is dedicated to broadening the reach of ADC development and manufacturing.